NextCell Pharma publishes quarterly report three 2017/2018

NextCell Pharma AB (”NXTCL”, “NextCell”) today, released its third quarter report 2017/2018
(September 2017 – May 2018).

Nine Months (2017-09-01 until 2018-05-31) 

  • Net sales amounted to SEK 527 545 (318 438).
  • Operating result amounted to SEK -10 610 012 (-8 477 749).                     
  • Result per share* amounted to SEK -1,25 (-2,89).
  • Cash and bank amounted to SEK 5 929 492 (6 558 898).
  • Solidity amounted to 83.8 (70.4)%.
  • Net sales amounted to SEK 136 341 (197 846).
  • Operating result amounted to SEK -3 085 756 (-3 614 243).                       
  • Result per sharez amounted to SEK -0.36 (-0.73).

Third quarter (2018-03-01 until 2018-05-31)

Significant events during the third quarter 2017/2018

In mid-March, NextCell entered into a partnership agreement with Nordic Tech House (NTH). where NTH, through a directed equity issue, becomes a shareholder in NextCell and will be responsible for NextCell’s digital presence with specific focus on stem cell treatments and family saving of stem cells via the Company’s brand name Cellaviva. 

At the end of March, NextCell announced that the Data and Safety Monitoring Board, for the clinical trial with ProTrans, approved that the principal investigator professor Per-Ola Carlsson and NextCell proceed with the treatment of three patients in the middle dose cohort. 

At the end of April, NextCell announced the signing of a Memorandum of Agreement with China General Consulting & Investment. The intention of the agreement is cooperation on stem cells in China. 

In mid-May, NextCell announced that, an additional three patients have been treated with ProTrans in the ongoing Phase I / II study. In total, six patients with type 1 diabetes in the low- and medium dose cohorts have undergone treatment. 

Significant events after the reporting period

At the end of June, NextCell announced that the Data and Safety Monitoring Board approves the treatment of three patients in the high dose cohort in the clinical trial with ProTrans. 

In the beginning of July, NextCell announced that a patent application was filed for a method for predicting if a specific patient is susceptible to treatment with the drug candidate ProTrans. 

At the end of July, NextCell announced the preparation for launching a stem cell service for adults during the first half of 2019. The stem cells are collected from adipose (fat) tissue by liposuction and allows adults to save their own stem cells for future use.

Stay up to date with the latest development in NextCell Pharma



For more information about NextCell Pharma AB, please contact:

Mathias Svahn, CEO

Leo Groenewegen, CFO

Phone: 08-735 5595


About NextCell Pharma AB:

Stem cells are expected to change the way how many of today's life-threatening diseases are treated. NextCell Pharma AB develops ProTrans, a drug candidate consisting of stem cells for the primary treatment of autoimmune and inflammatory diseases as well as for use in kidney transplants. ProTrans consists of selected stem cells derived from the umbilical cord tissue with NextCell Pharma AB's proprietary method. In addition, the company has a service called Cellaviva, Sweden's first and only IVO-approved stem cell bank for the family-saving of stem cells from umbilical cord blood and umbilical cord tissue.


Documents & Links